Safety of proteasome inhibitors for treatment of multiple myeloma

Cancer statistics, 2016

Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · see citing works

Cardiovascular Complications of Cancer Therapy

Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,276 · see citing works

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Hershman, D. L., Lacchetti, C., Dworkin, R. H., Smith, E., Bleeker, J. S., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,210 · see citing works

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920 · see citing works

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861 · see citing works

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A. P., Joshua, D., Pour, L., Hájek, R., Facon, T. T. F., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 858 · see citing works

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 776 · see citing works

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 681 · see citing works

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 656 · see citing works

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Richardson, P. G. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J. R., Singhal, S., Siegel, D. S. D., Irwin, D. H., Schuster, M. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 644 · see citing works

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

Kupperman, E., Lee, E. C. Y., Cao, Y., Bannerman, B. M., Fitzgerald, M., Berger, A., Yu, J., Yu, Y., Hales, P., Bruzzese, F. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 498 · see citing works

Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome

Groll, M., Berkers, C. R., Ploegh, H. L., & Ovaa, H. (2006) · Structure · doi:10.1016/j.str.2005.11.019 · Cited by 475 · see citing works

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446 · see citing works

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 433 · see citing works

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Arastu‐Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. H., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 411 · see citing works

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C. L., Trudel, S., Hentz, J. G., Noble, B. N., Pirooz, N. A., Spong, J., Píza, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 371 · see citing works

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Siegel, D. S. D., Martin, T. G., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L. M., Rajangam, K. L., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.089334 · Cited by 346 · see citing works

Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

Bross, P. F., Kane, R. C., Farrell, A. T., Abraham, S., Benson, K. A., Brower, M. E., Bradley, S. P., Gobburu, J. V. S., Goheer, A., Lee, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0781 · Cited by 344 · see citing works

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Lonial, S., Waller, E. K., Richardson, P. G. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1173 · Cited by 338 · see citing works

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D. E., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305 · see citing works

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Bréchignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278 · see citing works

Neuropathies Associated with Paraproteinemia

Ropper, A. H., & Gorson, K. C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805283382207 · Cited by 269 · see citing works

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

Miguel, J. F. S., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., Samoilova, O. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 263 · see citing works

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71125-8 · Cited by 262 · see citing works

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

Chanan-Khan, A. A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9641 · Cited by 262 · see citing works

Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258 · see citing works

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., et al. (2006) · Blood · doi:10.1182/blood-2006-09-046409 · Cited by 257 · see citing works

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Vij, R., Wang, M. L., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., Kukreti, V., Jagannath, S., McDonagh, K. T., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414359 · Cited by 254 · see citing works

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

Ruschak, A. M., Slassi, M., Kay, L. E., & Schimmer, A. D. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr160 · Cited by 243 · see citing works

How I treat Langerhans cell histiocytosis

Allen, C. E., Ladisch, S., & McClain, K. L. (2015) · Blood · doi:10.1182/blood-2014-12-569301 · Cited by 238 · see citing works

Bortezomib in recurrent and/or refractory multiple myeloma

Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R., Srkalović, G., Orlowski, R. Z., Richardson, P. G. G., Anderson, J. K., Nix, D., et al. (2005) · Cancer · doi:10.1002/cncr.20888 · Cited by 222 · see citing works

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202 · see citing works

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

Nooka, A. K., Kaufman, J. L., Muppidi, S., Langston, A. A., Heffner, L. T., Gleason, C. L., Casbourne, D., Saxe, D., Boise, L., & Lonial, S. (2013) · Leukemia · doi:10.1038/leu.2013.335 · Cited by 195 · see citing works

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Reeder, C. B., Reece, D. E., Kukreti, V., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271676 · Cited by 192 · see citing works

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Vij, R., Siegel, D. S. D., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K. T., Bahlis, N. J., Belch, A. R., Kunkel, L., Wear, S., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09232.x · Cited by 176 · see citing works

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedè, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 152 · see citing works

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Badros, A. Z., Vij, R., Martin, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.29 · Cited by 150 · see citing works

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Palumbo, A. P., Sezer, O., Kyle, R. A., Miguel, J. F. S., Orlowski, R. Z., Moreau, P., Niesvizky, R., Morgan, G. J., Comenzo, R. L., Sonneveld, P., et al. (2009) · Leukemia · doi:10.1038/leu.2009.122 · Cited by 144 · see citing works

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W., & Moreau, P. (2012) · Haematologica · doi:10.3324/haematol.2012.067793 · Cited by 127 · see citing works

Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis

Xiao, Y., Yin, J., Wei, J., & Shang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087671 · Cited by 124 · see citing works

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report

Voortman, J., & Giaccone, G. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-129 · Cited by 121 · see citing works

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Jagannath, S., Vij, R., Stewart, A. K., Trudel, S., Jakubowiak, A. J., Reiman, T., Somlo, G., Bahlis, N. J., Lonial, S., Kunkel, L., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.08.003 · Cited by 120 · see citing works

Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib

Hacıhanefioğlu, A., Tarkun, P., & Gonullu, E. O. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0139-7 · Cited by 107 · see citing works

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Papadopoulos, K. P., Siegel, D. S. D., Vesole, D. H., Lee, P., Rosen, S. T., Zojwalla, N. J., Holahan, J. R., Lee, S., Wang, Z., & Badros, A. Z. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3522 · Cited by 95 · see citing works

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Lendvai, N. K., Hilden, P. D., Devlin, S. M., Landau, H. J., Hassoun, H., Lesokhin, A. M., Tsakos, I., Redling, K., Koehne, G., Chung, D. J., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556308 · Cited by 82 · see citing works

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Kumar, S. K., LaPlant, B. R., Roy, V., Reeder, C. B., Lacy, M. Q., Gertz, M. A., Laumann, K. M., Thompson, M. A., Witzig, T. E., Buadi, F. K., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.60 · Cited by 80 · see citing works

Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature

Bockorny, M., Chakravarty, S., Schulman, P. M., et al. (2012) · Acta Haematologica · doi:10.1159/000340050 · Cited by 76 · see citing works

Therapy‐related peripheral neuropathy in multiple myeloma patients

Morawska, M., Grząśko, N., Kostyra, M., Wojciechowicz, J., & Hus, M. (2014) · Hematological Oncology · doi:10.1002/hon.2149 · Cited by 71 · see citing works

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Cavo, M., Pantani, L., Pezzi, A., Petrucci, M. T., Patriarca, F., Raimondo, F. D., Marzocchi, G., Galli, M., Montefusco, V., Zamagni, E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.274 · Cited by 71 · see citing works

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Moreau, P., Masszi, T., Grząśko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P. S., Baker, B. W., Jackson, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.727.727 · Cited by 68 · see citing works

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

Offidani, M., Corvatta, L., Caraffa, P., Gentili, S., Maracci, L., & Leoni, P. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s49187 · Cited by 58 · see citing works

Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

Gupta, N., Zhao, Y., Hui, A., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12542 · Cited by 56 · see citing works

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Durie, B. G. M., Hoering, A., Rajkumar, S. V., Abidi, M. H., Epstein, J., Kahanic, S. P., Thakuri, M. C., Reu, F. J., Reynolds, C. M., Sexton, R., et al. (2015) · Blood · doi:10.1182/blood.v126.23.25.25 · Cited by 56 · see citing works

Bortezomib-Cyclophosphamide-Dexamethasone (VCD)versusBortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis

Leiba, M., Kedmi, M., Duek, A., Freidman, T., Weiss, M., Leiba, R., Nagler, A., & Avigdor, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12946 · Cited by 49 · see citing works

Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients

Swaika, A., Paulus, A., Miller, K. C., Sher, T., Almyroudis, N. G., Ball, D., Wood, M., Masood, A., Lee, K. P., & Chanan-Khan, A. A. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.10.006 · Cited by 39 · see citing works

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Vesole, D. H., Bilotti, E., Richter, J. R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13517 · Cited by 35 · see citing works

Bortezomib-Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma

Gupta, A. K., Pandey, A., & Sethi, S. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-011-9146-7 · Cited by 30 · see citing works

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Diwadkar, S., Patel, A., & Fradley, M. G. (2016) · Case Reports in Cardiology · doi:10.1155/2016/3456287 · Cited by 30 · see citing works

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

Gupta, N., Huh, Y., Hutmacher, M. M., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2815-7 · Cited by 24 · see citing works

Low‐dose acyclovir prophylaxis for bortezomib‐induced herpes zoster in multiple myeloma patients

Minařík, J., Pika, T., Bačovský, J., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09233.x · Cited by 23 · see citing works

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Kaufman, J. L., Zimmerman, T. M., Rosenbaum, C. A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.32.32 · Cited by 23 · see citing works

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Dimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., et al. (2015) · Blood · doi:10.1182/blood.v126.23.26.26 · Cited by 15 · see citing works

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Gupta, N., Hanley, M. J., Harvey, R. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.4227.4227 · Cited by 5 · see citing works

Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies

Lonial, S., Colson, K., Harvey, R. D., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.232 · Cited by 3 · see citing works

Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies

Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59 · see citing works

Abstract 1768: Chloroquine potentiates carfilzomib but not bortezomib effects on myeloma cells

Misund, K., Baranowska, K. A., Holien, T., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-1768 · Cited by 1 · see citing works

Proteasome inhibition as a major advance in oncology

Coiffier, B. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)00045-x

Proteasome inhibitors

Teicher, B. A., & Tomaszewski, J. E. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.008 · Cited by 172 · see citing works

564 In vitro cytotoxic activity of NBT-272, a novel quassinoid analog

Helson, L., McChesney, J. D., & Bartyzel, P. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)80572-x · Cited by 2 · see citing works

Nonselective proteasome inhibitors in multiple myeloma and future perspectives

Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 12 · see citing works